What’s the latest innovation in CAR-T therapy? Fast-off, dual targeting, and other new tricks

During the 2020 Annual Meeting of the Society of Hematologic Oncology (SOHO), the ALL Hub was pleased to speak to Martin Pule, University College London, London, UK, about recent advances in chimeric antigen receptor (CAR) T-cell therapy for the treatment of ALL.

Martin Pule highlights treatment-related toxicities, long-term engraftment and antigen loss as major challenges for CAR T-cell therapy in the ALL setting. He then continues to discuss possible solutions to these hurdles, with the hope to improve the outlook of CAR T-cell-based treatments in ALL.